Updated Jul 16, 2026
McGuire Annie has filed 2 SEC Form 4 filings across 1 company in the last 90 days — selling. Lifetime open-market sales: $1.84M.
Annie Mcguire is the Senior Vice President and General Counsel at Veracyte, Inc., a genomic diagnostics company focused on cancer detection and treatment. She has been involved in multiple SEC filings related to her role, indicating her active participation in the company's legal and compliance matters.
| Role | EVP, General Counsel |
|---|---|
| Notability | 30/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-05 | VCYT | VERACYTE, INC. | S — Open-market sale | 1.8K | $50.12 | $89K |
| 2026-06-05 | VCYT | VERACYTE, INC. | S — Open-market sale | 1.4K | $49.31 | $69K |
| 2026-06-05 | VCYT | VERACYTE, INC. | F — Tax withholding / forfeiture | 3.3K | $47.80 | $157K |
| 2026-05-08 | VCYT | VERACYTE, INC. | S — Open-market sale | 5.1K | $40.00 | $204K |
| 2026-05-08 | VCYT | VERACYTE, INC. | S — Open-market sale | 5.1K | $38.05 | $194K |
| 2026-03-10 | VCYT | VERACYTE, INC. | A — Grant or award | 26.3K | $0.00 | |
| 2026-03-10 | VCYT | VERACYTE, INC. | A — Grant or award | 32.9K | $0.00 | |
| 2026-03-06 | VCYT | VERACYTE, INC. | S — Open-market sale [10b5-1] | 1.7K | $36.34 | $60K |
| 2026-03-06 | VCYT | VERACYTE, INC. | S — Open-market sale [10b5-1] | 5.0K | $35.29 | $176K |
| 2026-03-04 | VCYT | VERACYTE, INC. | F — Tax withholding / forfeiture | 6.9K | $36.01 | $249K |
| 2026-03-02 | VCYT | VERACYTE, INC. | F — Tax withholding / forfeiture | 10.9K | $38.75 | $421K |
| 2026-03-02 | VCYT | VERACYTE, INC. | A — Grant or award | 51.0K | $0.00 | |
| 2025-12-04 | VCYT | VERACYTE, INC. | S — Open-market sale [10b5-1] | 702 | $47.51 | $33K |
| 2025-12-04 | VCYT | VERACYTE, INC. | S — Open-market sale [10b5-1] | 720 | $47.10 | $34K |
| 2025-12-04 | VCYT | VERACYTE, INC. | F — Tax withholding / forfeiture [10b5-1] | 3.1K | $46.16 | $141K |
| 2025-10-01 | VCYT | VERACYTE, INC. | S — Open-market sale | 2.2K | $35.00 | $76K |
| 2025-09-19 | VCYT | VERACYTE, INC. | S — Open-market sale | 2.3K | $33.69 | $77K |
| 2025-09-02 | VCYT | VERACYTE, INC. | F — Tax withholding / forfeiture | 3.5K | $30.11 | $106K |
| 2024-12-06 | VCYT | VERACYTE, INC. | S — Open-market sale [10b5-1] | 18.7K | $44.02 | $823K |
| 2024-12-04 | VCYT | VERACYTE, INC. | F — Tax withholding / forfeiture | 1.9K | $44.12 | $85K |
Annie Mcguire is the Senior Vice President and General Counsel at Veracyte, Inc., a genomic diagnostics company focused on cancer detection and treatment. She has been involved in multiple SEC filings related to her role, indicating her active participation in the company's legal and compliance matters.…
2 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 11 open-market sales ($1.84M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live McGuire Annie profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.